3830 Federal Register / Vol. 87, No. 16 / Tuesday, January 25, 2022 / Notices 

Health, 6701 Rockledge Drive, Bethesda, MD 

20782, 301–402–4788, sarita.sastry@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

January 19, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–01358 Filed 1–24–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Diabetes Mellitus Interagency 

Coordinating Committee Meeting 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Diabetes Mellitus 

Interagency Coordinating Committee 

(DMICC) will hold a meeting on March 

8, 2022. The topic for this meeting will 

be ‘‘Opportunities for Research 

Supported by the Special Statutory 

Funding Program for Type 1 Diabetes 

Research.’’ The meeting is open to the 

public. 

DATES: The meeting will be held on 

March 8, 2022 from 8:30 a.m. to 4:45 

p.m. EDT. 

ADDRESSES: The meeting will be held 

via an online video conferencing 

platform. Virtual attendance for the 

meeting will be accessible to members 

of the public who register at https://

www.scgcorp.com/dmicc2022/ 

Registration at least 5 days prior to the 

workshop. 

FOR FURTHER INFORMATION CONTACT: For 

further information concerning this 

meeting, including a draft agenda, 

which will be posted when available, 

see the DMICC website, 

www.diabetescommittee.gov, or contact 

Dr. William Cefalu, Director, Division of 

Diabetes, Endocrinology, and Metabolic 

Diseases, National Institute of Diabetes 

and Digestive and Kidney Diseases, 

6707 Democracy Boulevard, Democracy 

2, Room 6037, Bethesda, MD 20892, 

telephone: 301–435–1011; email: 

dmicc@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 42 U.S.C. 285c–3, the 

DMICC, chaired by the National 

Institute of Diabetes and Digestive and 

Kidney Diseases (NIDDK) and 

comprising members of the Department 

of Health and Human Services and other 

federal agencies that support diabetesrelated activities, facilitates cooperation, 

communication, and collaboration on 

diabetes among government entities. 

DMICC meetings, held several times a 

year, provide an opportunity for 

Committee members to learn about and 

discuss current and future diabetes 

programs in DMICC member 

organizations and to identify 

opportunities for collaboration. The 

March 8, 2022 DMICC meeting will 

focus on ‘‘Opportunities for Research 

Supported by the Special Statutory 

Funding Program for Type 1 Diabetes 

Research.’’ Any interested person may 

file written comments with the 

Committee by forwarding their 

statement to the contact person listed on 

this notice. The statement should 

include the name, address, telephone 

number and, when applicable, the 

business or professional affiliation of 

the interested person. Because of time 

constraints for the meeting, there will 

not be time on the agenda for oral 

comments from members of the public. 

Members of the public who would 

like to receive email notification about 

future DMICC meetings should register 

for the listserv available on the DMICC 

website, www.diabetescommittee.gov. 

Dated: January 19, 2022. 

Bruce Tibor Roberts, 

Executive Secretary, DMICC, Office of 

Scientific Program and Policy Analysis, 

National Institute of Diabetes and Digestive 

and Kidney Diseases, National Institutes of 

Health. 

[FR Doc. 2022–01345 Filed 1–24–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer Institute 

Clinical Trials and Translational 

Research Advisory Committee. 

The meeting will be held as a virtual 

meeting and is open to the public. 

Individuals who plan to view the virtual 

meeting and need special assistance or 

other reasonable accommodations to 

view the meeting, should notify the 

Contact Person listed below in advance 

of the meeting. The meeting will be 

videocast and can be accessed from the 

NIH Videocasting and Podcasting 

website (http://videocast.nih.gov). 

Name of Committee: National Cancer 

Institute Clinical Trials and Translational 

Research Advisory Committee. 

Date: March 16, 2022. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: Strategic Discussion of NCI’s 

Clinical and Translational Research 

Programs. 

Place: National Cancer Institute, 9609 

Medical Center Drive, Rockville, MD 20850 

(Virtual Meeting). 

Contact Person: Sheila A. Prindiville, M.D., 

M.P.H., Director, Coordinating Center for 

Clinical Trials, National Cancer Institute, 

National Institutes of Health, 9609 Medical 

Center Drive, Room 6W136, Rockville, MD 

20850, 240–276–6173, prindivs@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: http://

deainfo.nci.nih.gov/advisory/ctac/ctac.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: January 19, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–01329 Filed 1–24–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 


khammond on DSKJM1Z7X2PROD with NOTICES